25 E. Pearson
Chicago, IL 60611
United States
Loyola University Chicago School of Law
SSRN RANKINGS
in Total Papers Downloads
in Total Papers Citations
intellectual property law, breast cancer, patent, European Patent Office, opposition, health care, research
gene patent, health care, research
electronic cigarettes, FDA, Family Smoking Prevention and Tobacco Control Act, marketing, promotion, safety
Gene editing, regulation, FDA
nanotechnology, FDA, drugs, medical devices, combination products, regulation
biosimilars, biologics, FDA, naming, substitution, health care, Biologics Price Competition and Innovation Act, Affordable Care Act
Biologics, Food and Drug Administration, biosimilars, Patient Protection and Affordable Care Act
incidental findings, human subjects research, bioethics, health law
gene patents, products of nature, process, USPTO, case law
Science Oversight, Technology Oversight, Dynamic Oversight, New Governance, Science Regulation, Technology Regulation, Nanotechnology, Nanobiotechnology, NNI, FDA, EPA, OSHA, NIOSH, NIH, OSTP, Law and Science, Bioethics
FDA, risk evaluation and mitigation strategies, REMS, anticompetitive, labeling, postmarket, generic drugs, drug approval
synthetic biology, FDA, safety, medical products
Biologics, FDA, Biologics Price Competition and Affordable Care Act
nanotechnology, regulation, oversight, federal agencies
nanotechnology, Food and Drug Administration, drugs, devices, biologics, health care reform
BRCA, patents, genetics research, health care, European Union, opposition
genetics research, biohistory, historical figures
pharmaceuticals, generic drugs, prescription drugs, mergers, consolidation, Federal Trade Commission, drug prices, antitrust
nanotechnology, nanobiotechnology, United States, oversight, law
nanotechnology, nanobiotechnology, law and science, technology oversight, science oversight, regulation of science and technology, emerging technologies, law and empirical studies. FDA, EPA, OSHA, NIOSH, NIH, RAC, USDA, NNI
United States Patent & Trademark Office, patent, claim, gene
USPTO, nanotechnology, patents, pharmaceuticals, drugs, claims, classification, science and law, technology and law, intellectual property law, federal agencies
incidental findings, genetics, research, informed consent, disclosure of results, law, ethics
Patient Advocacy, 21st Century Cures Act, FDA, Drugs, Devices, Biologics
Nanotechnology, nanobiotechnology, science and technology, emerging technology, oversight, oversight systems, empirical studies, expert elicitation, multi-criteria assessment, risk analysis, science regulation, oversight assessment, new governance, gene therapy, biotechnology, GMOs
Food and Drug Administration, nanotechnology, nanobiotechnology, drugs, medical devices, oversight
Precision medicine, companion diagnostics, drugs, medical devices, FDA, regulation, 21st Century Cures Act, innovation
genetics, research, patents, research exemption, international
electronic cigarettes, FDA, state laws, smoke-free, health, safety
BRAIN initiative, bioethics, federal funding, neuroscience, law
FDA, biosimilar, interchangeable, state laws, substitution
FDA, trans fat, regulations
FDA, nanotechnology, drug, biologic, device
generic drugs, labeling, proposed regulation, FDA, Supreme Court
